Mitral-specific cardiac damage score (m-CDS) predicts risk of death in functional mitral regurgitation: a study from the National Echo Database of Australia.

IF 2.8 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Avalon Moonen, David S Celermajer, Martin Kc Ng, Geoff Strange, David Playford, Simon Stewart
{"title":"Mitral-specific cardiac damage score (m-CDS) predicts risk of death in functional mitral regurgitation: a study from the National Echo Database of Australia.","authors":"Avalon Moonen, David S Celermajer, Martin Kc Ng, Geoff Strange, David Playford, Simon Stewart","doi":"10.1136/openhrt-2024-002841","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>We set out to explore associations between a 'mitral-specific' cardiac damage score (m-CDS) and survival outcomes in mitral regurgitation (MR) and compare the performance of the m-CDS and an 'aortic-specific' CDS (a-CDS) in patients with MR within the large National Echo Database of Australia.</p><p><strong>Methods: </strong>Among 620 831 unique adults investigated with echocardiography, there were 17 658 individuals (3.1%) with moderate or greater functional MR (aged 76±13 years, 51% female) who met inclusion criteria. A randomly selected cohort of 5000 of these patients was used to test seven different CDS models for prediction of subsequent all-cause mortality during an average 3.8-year follow-up. The best-performing CDS model in the <i>derivation cohort</i> was then applied to a <i>validation cohort</i> of the remaining 12 658 individuals (aged 76±13 years, 51% female).</p><p><strong>Results: </strong>The best-performing m-CDS model stratified the full cohort into Stage 0: control (1046 patients, 8%); Stage 1: left atrial damage (3416 patients, 27%); Stage 2: left ventricular damage (3352 patients, 26%); Stage 3: right ventricular damage (1551 patients, 12%) and Stage 4: pulmonary hypertension (3293 patients, 26%). Increasing m-CDS stage was consistently and incrementally associated with both all-cause and cardiovascular mortality at 1 year, 5 years and all-time and remained so after adjustment for increasing age and severity of MR, with a ~35% increase in mortality for each increase in CDS stage (p<0.001).</p><p><strong>Conclusion: </strong>A m-CDS was robustly and incrementally associated with short-, medium- and long-term risk of all-cause and cardiovascular mortality in patients with functional MR in this large registry study.</p>","PeriodicalId":19505,"journal":{"name":"Open Heart","volume":"11 2","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529689/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Heart","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/openhrt-2024-002841","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: We set out to explore associations between a 'mitral-specific' cardiac damage score (m-CDS) and survival outcomes in mitral regurgitation (MR) and compare the performance of the m-CDS and an 'aortic-specific' CDS (a-CDS) in patients with MR within the large National Echo Database of Australia.

Methods: Among 620 831 unique adults investigated with echocardiography, there were 17 658 individuals (3.1%) with moderate or greater functional MR (aged 76±13 years, 51% female) who met inclusion criteria. A randomly selected cohort of 5000 of these patients was used to test seven different CDS models for prediction of subsequent all-cause mortality during an average 3.8-year follow-up. The best-performing CDS model in the derivation cohort was then applied to a validation cohort of the remaining 12 658 individuals (aged 76±13 years, 51% female).

Results: The best-performing m-CDS model stratified the full cohort into Stage 0: control (1046 patients, 8%); Stage 1: left atrial damage (3416 patients, 27%); Stage 2: left ventricular damage (3352 patients, 26%); Stage 3: right ventricular damage (1551 patients, 12%) and Stage 4: pulmonary hypertension (3293 patients, 26%). Increasing m-CDS stage was consistently and incrementally associated with both all-cause and cardiovascular mortality at 1 year, 5 years and all-time and remained so after adjustment for increasing age and severity of MR, with a ~35% increase in mortality for each increase in CDS stage (p<0.001).

Conclusion: A m-CDS was robustly and incrementally associated with short-, medium- and long-term risk of all-cause and cardiovascular mortality in patients with functional MR in this large registry study.

二尖瓣特异性心脏损伤评分(m-CDS)可预测功能性二尖瓣反流的死亡风险:一项来自澳大利亚国家回声数据库的研究。
目的:我们旨在探索 "二尖瓣特异性 "心脏损伤评分(m-CDS)与二尖瓣反流(MR)患者生存结果之间的关系,并比较澳大利亚国家大型回声数据库中二尖瓣反流患者的 m-CDS 和 "主动脉特异性 "CDS(a-CDS)的表现:在接受超声心动图检查的 620 831 名成年人中,有 17 658 人(3.1%)患有中度或更严重的功能性 MR(年龄为 76±13 岁,51% 为女性),符合纳入标准。在平均 3.8 年的随访期间,随机抽取了其中的 5000 名患者,用于测试 7 种不同的 CDS 模型对后续全因死亡率的预测。然后,将衍生队列中表现最佳的 CDS 模型应用于由其余 12 658 人(年龄为 76±13 岁,51% 为女性)组成的验证队列:表现最佳的 m-CDS 模型将整个队列分为 0 期:对照组(1046 名患者,8%);1 期:左心房损伤(3416 名患者,27%);2 期:左心室损伤(3352 名患者,26%);3 期:右心室损伤(1551 名患者,12%)和 4 期:肺动脉高压(3293 名患者,26%)。m-CDS 阶段的增加与 1 年、5 年和所有时间的全因死亡率和心血管死亡率持续呈递增关系,在调整年龄和 MR 严重程度后仍是如此,CDS 阶段每增加一个阶段,死亡率增加约 35%(p 结论:m-CDS 阶段的增加与 1 年、5 年和所有时间的全因死亡率和心血管死亡率持续呈递增关系,在调整年龄和 MR 严重程度后仍是如此,CDS 阶段每增加一个阶段,死亡率增加约 35%:在这项大型登记研究中,m-CDS 与功能性 MR 患者的短期、中期和长期全因和心血管死亡风险密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Heart
Open Heart CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
3.70%
发文量
145
审稿时长
20 weeks
期刊介绍: Open Heart is an online-only, open access cardiology journal that aims to be “open” in many ways: open access (free access for all readers), open peer review (unblinded peer review) and open data (data sharing is encouraged). The goal is to ensure maximum transparency and maximum impact on research progress and patient care. The journal is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Opinionated discussions on controversial topics are welcomed. Open Heart aims to operate a fast submission and review process with continuous publication online, to ensure timely, up-to-date research is available worldwide. The journal adheres to a rigorous and transparent peer review process, and all articles go through a statistical assessment to ensure robustness of the analyses. Open Heart is an official journal of the British Cardiovascular Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信